1. Academic Validation
  2. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin

Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin

  • Eur J Pharmacol. 2005 Mar 7;510(1-2):9-16. doi: 10.1016/j.ejphar.2005.01.010.
Gerald Gimpl 1 Rolf Postina Falk Fahrenholz Torsten Reinheimer
Affiliations

Affiliation

  • 1 Institut für Biochemie, Becherweg 30, 55099 Mainz, Germany. gimpl@uni-mainz.de
Abstract

We have analyzed binding domains of the Oxytocin Receptor for barusiban, a highly selective Oxytocin Receptor Antagonist, in comparison to the combined vasopressin V1A/Oxytocin Receptor Antagonist atosiban and the agonists oxytocin and carbetocin. For this purpose, chimeric 'gain-in function' oxytocin/vasopressin V2 receptors were expressed in COS-7 cells. These recombinant receptors have been produced by transfer of domains from the Oxytocin Receptor into the related vasopressin V2 receptor and have already been successfully employed for the identification of ligand binding domains at the Oxytocin Receptor (Postina, R., Kojro, E., Fahrenholz, F., 1996. Separate agonist and peptide antagonist binding sites of the Oxytocin Receptor defined by their transfer into the V2 Vasopressin Receptor. J. Biol. Chem. 271, 31593-31601). In displacement studies with 10 chimeric receptor constructs, the binding profile of barusiban was compared with the binding profiles of the ligands oxytocin, [Arg8]vasopressin, carbetocin, and atosiban. The binding profiles for the agonists oxytocin and carbetocin were found to be similar. For both agonists, important binding domains were the extracellular N-terminus (=E1) and the extracellular loops E2 and E3 from the Oxytocin Receptor. For the vasopressin V1A/Oxytocin Receptor Antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor. In contrast, the binding of barusiban was significantly improved when the transmembrane domains 1 and 2 were transferred from the Oxytocin Receptor to the vasopressin V2 receptor. The binding domain of barusiban differs from the binding domain of the agonists and the nonselective Oxytocin Receptor Antagonist d(CH2)5[Tyr-(Me)2,Thr4,Orn8,Tyr9]vasotocin that has been used in previous studies. Overall, the data supported the concept of a central pocket site within the Oxytocin Receptor.

Figures
Products